A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone

Expert Review of Vaccines

Volumn 15, Issue 4, 2016, Pages 497-508

  Osorio, Jorge E ^a   Wallace, Derek ^b   Stinchcomb, Dan T ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Takeda Vaccines Pte Ltd   (Singapore)

^c Takeda Vaccines   (United States)

Author keywords

clinical immunology; Dengue; dengue endemic; dengueseropositive participants; live attenuated tetravalent vaccine; safety; TDV development

Indexed keywords

DENGUE VACCINE; GAMMA INTERFERON; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; PRM PROTEIN, FLAVIVIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADVERSE OUTCOME; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS REACTION; CYTOKINE RELEASE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE REACTION; JOINT SWELLING; MYALGIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PRIORITY JOURNAL; RASH; REVIEW; SEROCONVERSION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; BLOOD; DENGUE VIRUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; IMMUNOLOGY; PATHOLOGY; SEROTYPE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; SEROGROUP; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84959065544     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1128328     Document Type: Review

References (76)

1. Bhatt S, Gething PW, Brady OJ., et al. The global distribution and burden of dengue. Nature. 2013; 496: 504-507.
2. Impact of dengue. WHO; 2006 [cited 2015 Sep 2]. Available from: http://www.who.int/csr/disease/dengue/impact/en/
3. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control; 2009 [cited 2015 Sep 2]. Available from: http://books.google.com.sg/books?hl=en‎&id=dlc0YSIyGYwC&oi=fnd&pg=PP2&dq=dengue+anticoagulant+treatment&ots=OMuWEB5Im7&sig=-hMVWYfaCifFx-IoAtNWy3SJB3w#v=onepage&q=dengue%20anticoagulant%20treatment&f=false
4. Simmons CP, Farrar JJ, Nguyen VV., et al. Dengue. N Engl J Med. 2012; 366: 1423-1432.
5. WHO. Dengue and severe dengue: fact sheet No. 117; 2014 [cited 2014 Dec 10]. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/
6. Handbook for clinical management of dengue. World Health Organization; 2012 [cited 2014 Nov 5]. Available from: http://www.wpro.who.int/mvp/documents/handbook-for-clinical-management-of-dengue.pdf
7. Endy TP. Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Front Immunol. 2014; 5: 183.
8. Fried JR, Gibbons RV, Kalayanarooj S., et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis. 2010; 4: e617.
9. Bravo L, Roque VG, Brett J., et al. Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review. PLoS Negl Trop Dis. 2014; 8: e3027.
10. Limkittikul K, Brett J, LAzou M. Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review. PLoS Negl Trop Dis. 2014; 8: e3241.
11. Teixeira MG, Siqueira JB Jr., Ferreira GL., et al. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013; 7: e2520.
12. Dantes HG, Farfan-Ale JA, Sarti E. Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. PLoS Negl Trop Dis. 2014; 8: e3158.
13. Mohd-Zaki AH, Brett J, Ismail E., et al. Epidemiology of dengue disease in Malaysia (2000-2012): a systematic literature review. PLoS Negl Trop Dis. 2014; 8: e3159.
14. LAzou M, Taurel AF, Flamand C., et al. Recent epidemiological trends of dengue in the French territories of the Americas (2000-2012): a systematic literature review. PLoS Negl Trop Dis. 2014; 8: e3235.
15. Williams M, Mayer SV, Johnson WL., et al. Lineage II of Southeast Asian/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon. Am J Trop Med Hyg. 2014; 91: 611-620.
16. Vaughn DW, Green S, Kalayanarooj S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000; 181: 2-9.
17. Kouri GP, Guzman MG, Bravo JR., et al. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ. 1989; 67: 375-380.
18. Vu TT, Holmes EC, Duong V., et al. Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia. PLoS Negl Trop Dis. 2010; 4: e757.
19. Quiner CA, Parameswaran P, Ciota AT., et al. Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua. J Virol. 2014; 88: 13125-13134.
20. Guzman MG, Alvarez M, Rodriguez-Roche R., et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007; 13: 282-286.
21. Imrie A, Meeks J, Gurary A., et al. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol. 2007; 20: 672-675.
22. Halstead SB, Mahalingam S, Marovich MA., et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010; 10: 712-722.
23. Osorio JE, Huang CY, Kinney RM., et al. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011; 29: 7251-7260.
24. Osorio JE, Partidos CD, Wallace D., et al. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine. 2015;33:7112-7120.
25. Huang CY, Butrapet S, Tsuchiya KR., et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol. 2003; 77: 11436-11447.
26. Huang CY, Kinney RM, Livengood JA., et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013; 7: e2243.
27. Osorio JE, Brewoo JN, Silengo SJ., et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques. Am J Trop Med Hyg. 2011; 84: 978-987.
28. Brault AC, Kinney RM, Maharaj PD., et al. Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5 untranslated region and amino acid substitutions in nonstructural proteins 1 and 3. Vector Borne Zoonotic Dis. 2011; 11: 683-689.
29. Vaughn DW, Hoke CH Jr., Yoksan S., et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. 1996; 14: 329-336.
30. George SL, Wong MA, Dube TJT., et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naïve adults: a randomized, double-blind phase i clinical trial. J Infect Dis. 2015. DOI: 10.1093/infdis/jiv1179.
31. Bhamarapravati N, Yoksan S, Chayaniyayothin T., et al. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ. 1987; 65: 189-195.
32. Osorio JE, Velez ID, Thomson C., et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis. 2014; 14: 830-838.
33. Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I., et al. Safety and immunogenicity of a tetravalent dengue vaccine (TDV) in healthy children and adults in endemic regions: a randomized, placebo-controlled Phase 2 study. J Infect Dis. Forthcoming 2015.
34. Rupp R, Luckasen GJ, Kirstein JL., et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study. Vaccine. 2015;33:6351-6359.
35. Butrapet S, Huang CY, Pierro DJ., et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5 noncoding region and nonstructural proteins 1 and 3. J Virol. 2000; 74: 3011-3019.
36. Fuchs J, Chu H, ODay P., et al. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Vaccine. 2014; 32: 6537-6543.
37. Ambuel Y, Young G, Brewoo JN., et al. A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates. Front Immunol. 2014; 5: 263.
38. Shresta S, Kyle JL, Snider HM., et al. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol. 2004; 78: 2701-2710.
39. Guzman MG, Halstead SB, Artsob H., et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010; 8: S7-16.
40. Brewoo JN, Kinney RM, Powell TD., et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine. 2012; 30: 1513-1520.
41. Weiskopf D, Cerpas C, Angelo MA., et al. Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis. 2015; pii: jiv289.
42. Henriques HR, Rampazo EV, Goncalves AJ., et al. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge. PLoS Negl Trop Dis. 2013; 7: e2330.
43. Huang SS, Li IH, Hong PD., et al. Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus. Int J Nanomedicine. 2013; 8: 3161-3169.
44. Guirakhoo F, Kitchener S, Morrison D., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006; 2: 60-67.
45. Qiao M, Shaw D, Forrat R., et al. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011; 85: 724-731.
46. Guy B, Nougarede N, Begue S., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008; 26: 5712-5721.
47. Capeding MR, Tran NH, Hadinegoro SR., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384: 1358-1365.
48. Sabchareon A, Wallace D, Sirivichayakul C., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012; 380: 1559-1567.
49. Weiskopf D, Angelo MA, de Azeredo EL., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013; 110: E2046-2053.
50. Chu H, George SL, Stinchcomb DT., et al. CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis. 2015; pii: jiv258.
51. Weiskopf D, Angelo MA, Bangs DJ., et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2015; 89: 120-128.
52. Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol. 2014; 5: 93. DOI: 10.3389/fimmu.2014.00093.
53. Nguyet MN, Duong TH, Trung VT., et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A. 2013; 110: 9072-9077.
54. Guy B, Barrere B, Malinowski C., et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011; 29: 7229-7241.
55. Villar L, Dayan GH, Arredondo-Garcia JL., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372: 113-123.
56. Buddhari D, Aldstadt J, Endy TP., et al. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis. 2014; 8: e3230.
57. Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine. 2013; 31: 4501-4507.
58. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195-1206.
59. Durbin AP, Kirkpatrick BD, Pierce KK., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013; 207: 957-965.
60. Kirkpatrick BD, Durbin AP, Pierce KK., et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015; 212: 702-710.
61. Schwartz LM, Halloran ME, Durbin AP., et al. The dengue vaccine pipeline: implications for the future of dengue control. Vaccine. 2015; 33: 3293-3298.
62. ClinicalTrials.gov. Evaluating the safety and immune response to a dengue virus vaccine in healthy adults; 2014 [cited 2015 Sep 4]. Available from: http://clinicaltrials.gov/show/NCT02021968
63. ClinicalTrials.gov. Evaluating the safety and immune response to two doses of a dengue virus vaccine administered 12 months apart; 2014 [cited 2015 Sep 4]. Available from: http://clinicaltrials.gov/show/NCT01782300
64. ClinicalTrials.gov. Phase II trial to evaluate safety and immunogenicity of a dengue 1,2,3,4 (Attenuated) vaccine; 2015 [cited 2015 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01696422
65. ClinicalTrials.gov. Evaluating the safety of and immune response to a dengue vaccine (TV003) in healthy adults, adolescents, and children in Thailand; 2015 [cited 2015 Sep 4]. Available from: https://clinicaltrials.gov/show/NCT02332733
66. Coller BA, Clements DE, Bett AJ., et al. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine. 2011; 29: 7267-7275.
67. ClinicalTrials.gov. Evaluation of the safety and the ability of a DNA vaccine to protect against dengue disease (TVDV); 2015 [cited 2015 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01502358
68. World Health Organization. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. WHO/IVB/07.07; 2007 [cited 2015 Sep 16]. Available from: http://apps.who.int/iris/bitstream/10665/69687/1/who-ivb-07.07-eng.pdf
69. WHO. Global strategy for dengue prevention and control, 2012-2020; WHO/HTM/NTD/VEM/2012.5; 2012 [cited 2015 Sep 4]. Available from: http://www.who.int/immunization/sage/meetings/2013/april/5-Dengue-SAGE-Apr2013-Global-Strategy.pdf
70. Dengue Day 2015: interview With Dr. Joselito Sta. Ana. 2015 [cited 2015 Sep 2]. Available from: http://www.asianscientist.com/2015/06/features/dengue-day-2015-interview-dr-joselito-sta-ana/
71. ClinicalTrials.gov. Phase III trial to evaluate efficacy and safety of a tetravalent dengue vaccine; 2015 [cited 2015 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02406729
72. Chao DL, Halstead SB, Halloran ME., et al. Controlling dengue with vaccines in Thailand. PLoS Negl Trop Dis. 2012; 6: e1876.
73. Coudeville L, Garnett GP. Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination. PLoS One. 2012; 7: e51244.
74. Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Schwartz IB., et al. Potential opportunities and perils of imperfect dengue vaccines. Vaccine. 2014; 32: 514-520.
75. Mammen MP, Lyons A, Innis BL., et al. Evaluation of dengue virus strains for human challenge studies. Vaccine. 2014; 32: 1488-1494.
76. Sun W, Eckels KH, Putnak JR., et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis. 2013; 207: 700-708.